Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of neosaxitoxin for brachial plexus block in healthy volunteers
NL-OMON46410Phase 1Active, not recruiting
- Sponsor
- Grünenthal GmbH
- Start
- Nov 2016
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of neosaxitoxin, bupivacaine and epinephrine (10 arms), sponsored by Grünenthal GmbH. Primary endpoint: Primary safety and tolerability endpoint. Started Nov 2016; status: active, not recruiting.
02
Drugs
neosaxitoxinbupivacaineepinephrine
Beyond the preview
Go deeper on NL-OMON46410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46410.